-
Start Preamble
ACTION:
Notice of application.
DATES:
Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 6, 2020.
ADDRESSES:
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.33(a), this is notice that on July 19, 2019, Halo Pharmaceutical Inc., 30 North Jefferson Road, Whippany, New Jersey 07981-1030 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:
Controlled substance Drug code Schedule Dihydromorphine 9145 I Hydromorphone 9150 II The company plans to manufacture Hydromorphone (9150) for distribution to its customers. Dihydromorphone (9145) is an intermediate in the manufacture of Hydromorphone and is not for commercial distribution.
Start SignatureDated: October 22, 2019.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2019-24108 Filed 11-4-19; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 11/05/2019
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of application.
- Document Number:
- 2019-24108
- Dates:
- Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 6, 2020.
- Pages:
- 59646-59646 (1 pages)
- Docket Numbers:
- Docket No. DEA-527
- PDF File:
- 2019-24108.pdf